Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 1005

Next Previous
X
Search
Drug Profile

AB 1005

Alternative Names: AAV2-GDNF; AAV2-GDNF-MSA; AAV2-GDNF-PD; AB-1005; Adeno-associated-virus-GDNF-therapy-Brain Neurotherapy Bio; AMT-140; GDNF gene therapy - Brain Neurotherapy Bio; Glial cell line derived neurotrophic factor gene therapy-Brain Neurotherapy Bio

Latest Information Update: 17 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Asklepios BioPharmaceutical; Brain Neurotherapy Bio; Lund University; uniQure
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease
  • Phase I Multiple system atrophy

Most Recent Events

  • 11 Jul 2024 AB 1005 receives Fast Track designation for Parkinson's disease [Intracerebral,Infusion] in USA
  • 11 Jul 2024 AB 1005 receives Innovation Passport designation from the MHRA for Parkinson’s disease in the UK
  • 03 Jul 2024 Asklepios BioPharmaceutical plans to initiate phase II (REGENERATE-PD) trial for Parkinson Disease (Intracerebral, Infusion) in the United Kingdom and Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top